|
Synonyms: ORY-1001 | ORY1001 | RG-6016
Compound class:
Synthetic organic
Comment: Iadademstat (ORY-1001; Oryzon Genomics) is a selective and irreversible inhibitor of lysine (K)-specific demethylase 1A (KDM1A, aka LSD1) [2]. Structurally it is a derivative of tranylcypromine. LSD1 inhibition enhances H3K4 methylation and increases the expression of tumour suppressor genes. ORY-1001 is claimed in patent WO2010084160A1 [1]. We provide the structure for the parent compound and the dichloride salt is represented in PubChem CID 71664305.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
|||||||||||||||||||||||||||||||||||
| No information available. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05546580 | Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+) | Phase 1 Interventional | Oryzon Genomics S.A. | ||
| NCT06287775 | Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer | Phase 1/Phase 2 Interventional | National Cancer Institute (NCI) | ||
| NCT06661915 | A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) | Phase 2 Interventional | National Cancer Institute (NCI) | ||